Novartis AG

Novartis AG

Novartis AG

Overview
Date Founded

1996

Headquarters

Lichtstrasse 35, Basel, 4056, CHE

Type of Company

Public

Employees (Worldwide)

104K

Industries

Pharmaceuticals
Hospitals & Patient Services
Wholesale: Consumer Non-Durables/Sundries
Biotechnology

Company Description

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Contact Data
Trying to get in touch with decision makers at Novartis AG? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Group General Counsel of Novartis

Chief Technology & Digital Officer

Chief Medical Officer

Chief Digital Officer

Chief Executive Officer, Sandoz

Global Head of Novartis Business Assurance & Advisory & Head of Internal Audit

Head of Novartis Business Services (Nbs)

Ad Interim Global Head of Strategy

Board of Directors

Former Chief Operating Officer at Novartis Corporation

N at Novartis Corporation

Group Chief Executive Officer & Executive Director at Standard Chartered PLC

Scientific Founder at Blueprint Medicines Corp.

Future Dean at Harvard University - Harvard Business School (Effective 01/2021)

Former Executive Vice President & President, Consumer Care at Merck & Co., Inc.

Former Chairman & Chief Executive Officer at Young & Rubicam Brands, Inc.

President & Chief Executive Officer at Koninklijke Philips NV

Executive Vice President & Head of Strategic Business Units, Marketing, Sales & Nespresso at Nestlé SA

Partner at Lenz & Staehelin AG

Paths to Novartis AG
Potential Connections via
Relationship Science
You
Novartis AG
Owners & Shareholders
Details Hidden

UBS Asset Management Switzerland offers investment capabilities across all major traditional and alternative asset classes.

Details Hidden

NBIM is an active, conservative manager with a long-term outlook that aims to achieve the highest possible return on the Government Pension Fund Global within the investment mandate set by the Ministry of Finance, which owns the fund on behalf of the Norwegian people. The ministry determines the fund’s investment strategy, following advice from among others, NBIM and discussions in Parliament. The firm’s mandate defines the investment universe and the fund's strategic reference index. The Ministry of Finance has on a regular basis transferred capital to the fund from the Norwegian state's petroleum revenues. The fund's capital is invested abroad, to avoid overheating the Norwegian economy and to shield it from the effects of oil price fluctuations. The fund invests in international equity and fixed-income markets and real estate. It is invested in most markets, countries and currencies to achieve broad exposure to global economic growth. The investments are to produce a high long-term return. NBIM aims to achieve this this with an acceptable level of risk, as a responsible investor and through an efficient organization.

Details Hidden

WMC relies on their extensive independent research and include portfolio management styles and approaches in equities, fixed income securities, currencies and commodities, as well as asset allocation across these categories. The firm has a number of different disciplines when approaching research and these include asset allocation analysts, currency analysts, data scientists, factor analysts, fixed income credit analysts, fixed income market analysts, global industry analysts and research associates, macro-analysts, quantitative analysts and technical analysts. WMC’s portfolio management teams often include dedicated analysts who evaluate securities and other instruments for suitability based on the team’s investment approach. The firm supplements their internal research with external research from sources such as broker/dealers and third-party research firms. These sources typically provide data, research and analysis and may serve as a gauge of market consensus.

Recent Transactions
Details Hidden

Novartis AG purchases Amblyotech, Inc.

Details Hidden

Novartis AG purchases The Medicines Co.

Details Hidden

Novartis AG purchases Takeda Pharmaceutical Co. Ltd. /Xiidra Business from Takeda Pharmaceutical Co., Ltd.

Transaction Advisors
Legal Advisor

Advised onNovartis AG purchases Chiron Corp.

Accountant

Advised onNovartis AG purchases Chiron Corp.

Investment Advisor

Advised onNovartis AG purchases Alcon, Inc. from Nestlé SA

Legal Advisor

Advised onNovartis International AG, Novartis AG purchase AveXis, Inc.

Co-Chair, Corporate Group

Advised onNovartis AG purchases Alcon, Inc. from Nestlé SA

Legal Advisor

Advised onEli Lilly & Company purchases Elanco Tiergesundheit AG from Novartis AG

Advisors & Consultants
Consultant

The Energy Project energizes people and transforms companies, offering a detailed blueprint for fueling a fully engaged workforce. Drawing on the multidisciplinary science of high performance, we do this at three levels: We train people to perform sustainably at the highest levels by more skillfully managing their energy across four dimensions: physical, emotional, mental and spiritual to develop actionable strategies that help them to become more energized, focused and productive. We teach leaders to become Chief Energy Officers, who mobilize, inspire, focus, direct and regularly recharge the energy of those they lead. We partner with companies to help them better meet the core needs of their employees, so they’re freed, fueled and inspired to bring the best of themselves to work every day. Demand is exceeding our capacity. Time is the resource we’ve traditionally relied on to get more done. The problem with time is that it’s finite, and most of us no longer have additional hours left to invest at work. Energy, by contrast, can be expanded and regularly renewed. Drawing on the multidisciplinary science of high performance, The Energy Project has developed a set of simple principles and highly actionable practices for more effectively managing energy to drive higher levels of engagement, productivity, and innovation. Our clients range from companies such as Google, Coca Cola, Target, Sony, Ernst & Young, and Pfizer to organizations such as the Los Angeles Police Department, the Cleveland Clinic, Kipp Schools and many others.

Legal Advisor

Shareholder at Greenberg Traurig LLP

Legal Advisor

Partner at Winston & Strawn LLP

Legal Advisor

Partner at Winston & Strawn LLP

Clients

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a pharmaceutical services provider based in China, focusing on marketing promotion and sales of prescription drugs to all therapeutic departments in hospitals. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007, the Group was listed on Main Board Market in Hong Kong on 28 September 2010 while it was delisted on AIM at the same time. The Group follows two business models which can be commonly found in the pharmaceutical industry in China, the Direct Academic Orientated Promotion Model and Agency Promotion Model, and with two distinct third party promotion networks, the Direct Academic Orientated Promotion Network (the “Direct Network”) and the Agency Promotion Network (the “Agency Network”), both of which hold leading positions in the Chinese market. On the 3 April 2011, the Group successfully acquired Great Move Enterprise Limited (“Great Move”) and its subsidiaries, the main wholly subsidiary of Great Move is Tianjin Precede Medical Trade Development Co., Ltd.(which has been officially renamed Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd.on 24 October 2011), which mainly engages in the marketing, promotion and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies via Agency Network in China. After the acquisition, the Group` business model evolved from simply depending on internal marketing and promotion team to promote and sell products directly to physicians (Direct Academic Orientated Promotion Model) to a new integrated development model that incorporates the independent third party sales representatives and distributors to sale and promote products (Agency Promotion Model) in China. On the 31 May 2011, the Group successfully acquired 51% equity interests of Guangming Pharmaceutical Co., Ltd. (which has been officially renamed Guangxi Kangzhe Guangming Pharmaceutical Co., Ltd. on 10 October 2011) via cash investment for capital and stock increase to gain the permanent China market rights of a type of enteral nutrition drug-“Protein Hydrolysate”. The speedy introduction of this product is the result of the combination of the professional academic ability from our Direct Network and the rapid market coverage ability of our Agency Network. We introduce drugs that prove to be competitive and focus on providing marketing, promotion and sales services to specialty pharmaceutical companies by leveraging our successful product selection system and the insights in Chinese pharmaceutical market. As at 31 December 2011, the Direct Network of the Group had close to 1,200 sales, marketing and promotion professionals; the Agency Network had close to 1,000 independent third party sales representatives or distributors and around a hundred of senior regional and marketing managers. The Group`s sales coverage spanned over 14,600 hospitals throughout China, of which almost 8,600 hospitals were covered by the Direct Network and over 7,800 hospitals were covered by the Agency Network. The Group follows a market-oriented product selection strategy and introduces prescription drugs with high growth potential under its Direct Academic Orientated Promotion Model. We formulate appropriate marketing strategies for each drug, leveraging the insights in the Chinese pharmaceutical market, prevailing treatment protocols of physicians, demographic profile of the relevant patient pool in China and potential competitive advantages of drugs. Meanwhile, in order to help drive demand for pharmaceutical products, our professional, stable and experienced marketing, promotion and sales team conducts various physician-oriented academic promotion activities such as one-on-one physician visits, medical symposia and industry conferences, and via our proprietary information management system to keep track of these activities and review operations in a timely manner, enabling us to manage our overall business effectively and efficiently. In addition, the Group also provides other ancillary services needed by pharmaceutical companies to introduce their products to China, including handling product registration, clinical trials, and bidding in collective tender processes. With appropriate product positioning, strategic planning and execution, the Group gained remarkable performance. From 2007 to 2011, the compound annual growth rate (CAGR) of revenue was 42.0%, and the CAGR of net profit achieved 63.7%. We also received a number of recognitions, including the Group was ranked in the list of Forbes “Asia’s Best 200 Enterprises Under a Billion” in 2008 and “Top 100 Enterprises in Shenzhen” in 2009, 2010 and 2011, and we also gained Forbes “China’s Best Up-and-Coming Business” three times in 2010, 2011 and 2012. As a leading China-based pharmaceutical services company, the Group established long-term business partnership with specialty pharmaceutical companies from Germany, Denmark, Ireland, France, Ukraine, Japan and China. We will continuously introduce new products and extend marketing, promotion and sales network to strengthen our leading position in Chinese pharmaceutical service market, and through the professional and quality service to catch opportunities from the enormous growth of Chinese pharmaceutical market and strives to become the preferred partner for overseas and domestic pharmaceutical companies who target at Chinese market.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Key Stats and Financials As of 2019
Market Capitalization
$192B
Total Enterprise Value
$234B
Earnings Per Share
$3.1
EBITDAMargin
33.51%
Enterprise Value / Sales
4.88x
Enterprise Value EBITDAOperating
14.56x
TEVNet Income
32.92x
Debt TEV
0.12x
Three Year Compounded Annual Growth Rate Of Revenue
-0.42%
Revenue
$47.9B
Net Profit
$7.1B
EBITDA
$16B
Total Debt
$28.6B
Total Equity
$54.6B
Investments
Details Hidden

Vineti, Inc. develops software for scaling and digital solutions for cell and gene therapies. The firm focuses on enabling life changing autologous therapies, supporting standards, and developing infrastructure that will expand patient access through expedited discovery, delivery and regulation in the field. The company was founded by Heidi Hagen, Malek Faham, Amy DuRoss and Razmik Abnous and is headquartered in Menlo Park, CA.

Details Hidden

Freenome Holdings, Inc. engages in the development of multiomics platform for early cancer detection. It develops simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. The company was founded by Charles Roberts, Riley Ennis, and Gabriel Otte and is headquartered in South San Francisco, CA.

Details Hidden

Science 37, Inc. develops mobile technology, clinical trials and patient-centric models for clinical research. It focuses on the development of networked patient-centric models for clinical research to accelerate biomedical discovery. The firm develops Network Oriented Research Assistant, which bridges the gap between traditional trial management software and an advanced telemedicine platform; supports end-to-end management of networked clinical trials; and allows researchers to communicate with patients and mobile nurses from homes using videos, photographs, survey forms, or device data capture on iPhones, iPads, or Android devices. The company was founded by Noah Craft and Belinda Tan and is headquartered in Culver City, CA.

Investors
Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Managing Partner at Amzak Capital Management LLC

Suppliers
AptarGroup, Inc. Personal Products | Crystal Lake, IL

AptarGroup, Inc. develops manufactures and sales of consumer product dispensing systems. It operates through the following business segments: Beauty & Home, Pharma and Food & Beverage. The Beauty & Home segment primarily sells pumps, aerosol valves and accessories to the personal care and household markets and pumps and decorative components to the fragrance/cosmetic market. The Pharma segment supplies pumps and metered dose inhaler valves to the pharmaceutical market worldwide. The Food & Beverage segment sell dispensing and non-dispensing closures and, to a lesser degree, spray pumps and aerosol valves to the food and beverage markets. The company was founded in 1940 and is headquartered in Crystal Lake, IL.

Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Veeva Systems, Inc. Other Business & Consulting Services | Pleasanton, CA

Veeva Systems, Inc. provides industry-specific, cloud-based software solutions for the life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage a regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. Veeva Systems was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007 and is headquartered in Pleasanton, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Novartis AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Novartis AG's profile does not indicate a business or promotional relationship of any kind between RelSci and Novartis AG.